Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | RORC | P51449 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30168169 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2CYP19A1RORCMAPTNPSR1 | |
| SCHEMBL7121721 | 0.90 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP19A1RORCMAPTNPSR1 | |
| SCHEMBL28639117 | 0.89 | SMN1; SMN2 (0.54) | SMN1; SMN2CYP19A1RORCMAPTNPSR1 | |
| SCHEMBL9445656 | 0.88 | SMN1; SMN2 (0.63) | SMN1; SMN2CYP19A1RORCHTTKMT2A | |
| SCHEMBL29940631 | 0.87 | CYP1A2 (0.56) | SMN1; SMN2CYP19A1RORCMAPTNPSR1 | |
| SCHEMBL28639119 | 0.87 | CYP19A1 (0.58) | SMN1; SMN2CYP19A1RORCMAPTNPSR1 | |
| SCHEMBL9212980 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2CYP19A1RORCMAPTNPSR1 | |
| SCHEMBL11722866 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2CYP19A1RORCMAPTNPSR1 | |
| SCHEMBL9222183 | 0.84 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP19A1RORCMAPTNPSR1 | |
| SCHEMBL29940373 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2CYP19A1MAPTNPSR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4161930-A1 | NOVEL IMIDAZO-PYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| CN-115667264-A | Novel imidazo-pyrazine derivatives | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021249893-A1 | NOVEL IMIDAZO-PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | disclosed |
| US-9701691-B2 | Thienopyrimidine compounds | HOFFMAN-LA ROCHE INC. (US) | 2017-07-11 | — | — | US | disclosed |
| EP-2802590-B1 | THIENOPYRIMIDINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-03-01 | — | — | EP | disclosed |
| EP-2802590-A1 | THIENOPYRIMIDINE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2014-11-19 | — | — | EP | disclosed |
| CN-104159904-A | Thienopyrimidine compounds | HOFFMANN LA ROCHE | 2014-11-19 | — | — | CN | disclosed |
| WO-2013104575-A1 | THIENOPYRIMIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-18 | — | — | WO | disclosed |
| US-20130178460-A1 | THIENOPYRIMIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | DIXON BRIAN R (US) | 2003-11-06 | — | — | US | disclosed |
| US-6353006-B1 | TREATMENT OF BONE DISORDERS, OSTEOPOROSIS AND HEALING AGENT | BAYER CORPORATION | 2002-03-05 | — | — | US | disclosed |
| EP-1144396-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | Bayer Corporation (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042031-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | XDH, MYD88, IKZF3 | SMN1; SMN2 2032/4885CYP19A1 2699/4885RORC 1103/4885 |
| US-20130178460-A1 | THIENOPYRIMIDINE COMPOUNDS | SYK, BTK, LCK | SMN1; SMN2 4369/4885CYP19A1 2083/4885RORC 325/4885 |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | PGR, PGRMC2, PGRMC1 | SMN1; SMN2 4733/4885CYP19A1 19/4885RORC 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.